Antibacterial activity of cinoxacin in vitro.
Cinoxacin is a new synthetic compound similar chemically and in antimicrobial activity to oxolonic acid and nalidixic acid. It is most effective against Escherichia coli and Proteus mirabilis, but at concentrations expected in the urine it is inhibitory for all species of Enterobacteriaceae. Relative to nalidixic acid, cinoxacin has slightly greater inhibitory and bactericidal activity, less inoculum effect probably due to less heterogeneity in the susceptibility of bacterial cells, and less inhibition by high concentrations of serum protein. Both drugs are more active in an acid than an alkaline medium. Glucose can specifically antagonize the inhibitory effect against P. mirabilis. In urine the bactericidal rate and effect are decreased. Resistance to cinoxacin can be developed quickly by serial transfers in vitro. Some nonresistant organisms remained viable in bactericidal drug concentrations. The in vivo importance of the favorable features of cinoxacin must be determined by clinical trials.
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D004148:Dioxolanes / Q000494:pharmacology; D004755:Enterobacteriaceae / Q000187:drug effects*; D004926:Escherichia coli / Q000187:drug effects*; D009268:Nalidixic Acid / Q000494:pharmacology; D011513:Proteus mirabilis / Q000187:drug effects*; D011724:Pyridazines / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D004148:Dioxolanes; D011724:Pyridazines; D009268:Nalidixic Acid